A BRCA Mutation Does Not — Mean You Will Get Cancer

Yes, and the difference affects both your risk level and the timing of key decisions. BRCA1 carries a higher lifetime ovarian cancer risk — around 44% compared to around 17% for BRCA2. BRCA1-related breast cancers are also more likely to be triple-negative, a subtype with fewer targeted treatment options. BRCA2 is associated with a higher risk of male breast cancer and pancreatic cancer. The distinction shapes which surveillance steps your oncologist will prioritise and when risk-reducing surgery is typically recommended.

It depends on how the test was done and on your family history. If a specific BRCA mutation is already known in your family and you tested negative for that exact mutation, the result is very reassuring. But if no mutation has been identified in your family and you received a broad negative result, it does not rule out all hereditary risk — another gene may be responsible. A genetic counsellor can explain what your specific result means before you conclude that you are at average risk.

Most genetic counsellors and NCCN guidance recommend waiting until a child is old enough to make an informed decision for themselves — usually age 18 or older. Surveillance for BRCA carriers typically begins in the mid-twenties, so there is no screening action that makes early testing in childhood medically urgent. What matters now is that you record your result clearly and share it with your children when they are ready to decide about testing. There is time, and that time is worth using to do it well.

Yes. Men who carry BRCA2 face a lifetime breast cancer risk of around 7%, compared to less than 1% in the general male population, as well as an increased risk of prostate and pancreatic cancer. BRCA1 in men also raises prostate cancer risk. If you are a man who has found out about your BRCA status through a female relative's result, ask your oncologist what surveillance applies to you specifically. Male carriers are often not told that a monitoring programme exists for them — and it does.

It reduces risk substantially — it does not eliminate it entirely. ASCO estimates that removing the ovaries and fallopian tubes before cancer appears reduces ovarian cancer risk by around 80 to 95% in BRCA carriers. It also reduces breast cancer risk in women who have not yet reached menopause. Preventive mastectomy reduces breast cancer risk by over 90%, according to ASCO data. A small residual risk remains because not all at-risk tissue can be removed. Both decisions carry significant physical and emotional consequences and deserve unhurried discussion with your oncologist and, where possible, a second opinion.

India does not currently have a law requiring you to disclose genetic test results to health insurers, and no established regulatory framework allows insurers to price policies based solely on genetic status. However, the insurance landscape is still developing. If this is a concern, speak to your genetic counsellor before making any insurance decisions. Do not let anxiety about insurance delay testing — knowing your BRCA status is too important to your health to withhold from yourself.